|
VHL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.60860025089482E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.04659999999868E-07 |
| Normal-vs-Stage2 |
1.96675999999396E-05 |
| Normal-vs-Stage3 |
8.8474000348171E-09 |
| Normal-vs-Stage4 |
5.69070000011607E-08 |
| Stage1-vs-Stage2 |
5.999400E-01 |
| Stage1-vs-Stage3 |
1.383410E-01 |
| Stage1-vs-Stage4 |
6.204200E-02 |
| Stage2-vs-Stage3 |
5.872800E-01 |
| Stage2-vs-Stage4 |
3.546600E-01 |
| Stage3-vs-Stage4 |
6.340600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.84710002848476E-09 |
| Normal-vs-AfricanAmerican |
9.057000E-03 |
| Normal-vs-Asian |
1.60841999999883E-05 |
| Caucasian-vs-AfricanAmerican |
2.955000E-01 |
| Caucasian-vs-Asian |
9.165600E-01 |
| AfricanAmerican-vs-Asian |
2.963000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.34720000500144E-08 |
| Normal-vs-Female |
2.29329999434924E-09 |
| Male-vs-Female |
7.485800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.21769999997345E-06 |
| Normal-vs-Age(41-60Yrs) |
2.5276000181762E-09 |
| Normal-vs-Age(61-80Yrs) |
1.6586999995738E-08 |
| Normal-vs-Age(81-100Yrs) |
1.127560E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.367600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.801400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.552800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.899600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.927400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.062800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.223500E-02 |
| Classical-VS-Follicular |
5.227500E-02 |
| Classical-VS-Other |
3.479600E-01 |
| Classical-VS-Normal |
1.13969999993024E-07 |
| Tall-VS-Follicular |
3.945400E-01 |
| Tall-VS-Other |
8.761400E-01 |
| Tall-VS-Normal |
1.20920000012958E-07 |
| Follicular-VS-Other |
8.032000E-01 |
| Follicular-VS-Normal |
1.49819999961665E-07 |
| Other-VS-Normal |
1.226060E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.27999999991013E-08 |
| Normal-vs-N1 |
6.77730005449462E-09 |
| N0-vs-N1 |
4.289500E-02 |
|
|
